-- Sunshine Lake Pharma's (HKG:6887) insulin glargine injection was approved by the U.S. Food and Drug Administration, the firm said Monday.
The medicine, a biosimilar version of Sanofi's Lantus, is intended to treat children with type 1 diabetes and adults with type 2 diabetes.
The injection will be available under the Langlara trade name.